Fichot twenie' 20140123

About Invectys

Invectys is a biopharmaceutical company focused on the development of innovative immunotherapy approaches to treat cancers. Invectys exploits novel approaches to restore and mobilize the anti-tumor ability of the immune system of cancer patients. Therapeutic vaccination strategies allow targeting of practically all cancers. Invectys converged on the universal tumor antigen telomerase that plays a critical role in uncontrolled cell growth.

More
3987bff89a_cellule-souche-embryonnaire_Eugene_Russo-Plos-cc_by_25

A DNA vaccine targeting telomerase

The main product of Invectys is a DNA vaccine targeting Telomerase. Vaccination using DNA as a source of antigen is a technology with many advantages compared to conventional approaches. The antigen is expressed endogenously and presented to both MHC class I and II molecules to lead a cell-mediated and humoral immune responses. DNA-based products are […]

More

News

IN VAC-1

New success for the therapeutic vaccine INVAC-1 for patients with cancer

With 7 million raised in the last year and excellent results in terms of tolerance and innocuity, Invectys opens up new hopes in cancer immunotherapy Paris, March 18th 2016 – Invectys announces today success with its therapeutic vaccine INVAC-1 that shows excellent innocuity and high tolerance in patients. During the third stage of the ongoing […]

More
Money Euro

Invectys raises a further 7 million euros to accelerate clinical development of its therapeutic cancer vaccine

With more than 17 million euros raised in total Invectys also benefits from 850,000€ in financing from Bpifrance. Invectys announces fundraising of an additional 7 million euros from its original group of private investors to accelerate clinical development of its therapeutic anti-cancer vaccine, INVAC-1, that is near the end of phase I.

More
Test tubes closeup.medical glassware

Invectys starts the third dose level of its phase I clinical trial evaluating INVAC-1, an innovative anti-cancer therapeutic vaccine

Invectys starts the third dose level of its phase I clinical trial evaluating INVAC-1, an innovative anti-cancer therapeutic vaccine  A new clinical hope in cancer immunotherapy October 30th, 2015 Paris – Invectys announces today the start of the third and last dose level in the phase I clinical trial (INVAC1-CT-101) evaluation of its immunotherapeutic drug […]

More
fotolia_88631029

Invectys raises 1.7 million Euros more to finance the clinical development of its therapeutic cancer vaccine

Invectys raises 1.7 million Euros more to  finance the clinical development of its therapeutic cancer vaccine With a total of 10 million euros raised, new premises, new labs and new equipment, Invectys is ready for the clinic Paris, March 30, 2015 – Invectys announces today a fundraising of an additional 1.7M€ from its original group […]

More
fotolia_54048895 (1)

Invectys Initiates Phase I Clinical Trial Evaluating INVAC-1 Therapeutic Vaccine for Cancer Patients

Invectys Initiates Phase I Clinical Trial Evaluating INVAC-1 Therapeutic Vaccine for Cancer Patients A new clinical hope in cancer immunotherapy Paris, May 12th, 2015 – Invectys announces today that it has initiated a phase I clinical trial of its immunotherapeutic drug candidate INVAC-1. INVAC-1 is an innovative therapeutic DNA vaccine, which specifically targets the telomerase […]

More
fotolia_80101677

Invectys receives ANSM approval to start clinical trial for INVAC-1, its leading anticancer immunotherapy

Invectys receives ANSM approval to start clinical trial for INVAC-1, its leading anticancer immunotherapy INVAC-1 is an anticancer candidate vaccine targeting telomerase activity in cancer cells Paris, September 29, 2014 – Invectys announces today that its leading anticancer candidate vaccine INVAC-1 has received authorization from the French Medicine Agency, ANSM (Agence Nationale de Sécurité du Médicament et des […]

More